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Abstract  Stroke  represents  a  public  health  enemy.  Currently,  and  in  spite  of  multiple  clinical
trials, thrombolysis  remains  as  the  only  approved  therapy.  Most  preclinical  trials  and  animal
trials employing  stem  cell-based  therapies  have  shown  very  promising  evidence  of  beneﬁts.
The aim  of  this  review  is  to  provide  a  landscape  of  what  has  been  done  in  human  clinical  trials,
and what  are  the  possible  ways  that  stem  cell  therapy  may  enhance  functional  recovery  in
stroke patients.Hematopoietic  stem
cells;
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Acute  stroke  is  the  sixth  most  common  cause  of  death  among
Mexicans  and  the  third  cause  in  elderly  people;  just  in  2014
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CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4t  was  responsible  for  30,000  deaths.1 Though  these  numbers
ay  even  be  sub-registered.2 More  startling  is  the  fact  that
troke  is  the  leading  cause  of  disability  in  this  country  and
orldwide.3 This  is  because  in  spite  of  the  high  mortality,
5%  of  patients  survive  a  stroke  with  some  kind  of  sequel;
his  is  258  patients  daily.4
The  main  mid-term  and  long-term  sequels  of  stroke
re  dysphagia,  fatigue,  muscle  weakness,  paralysis,  visual
roblems,  incontinence,  chronic  pain,  seizures,  insom- Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
ia,  depression,  dementia,  aphasia,  amnesia  among  many
thers.5
The  annual  incidence  of  stroke  is  232/100,000  people,
ith  a  prevalence  of  8/1000.6 With  a  population  of  112
asson Doyma Me´xico S.A. This is an open access article under the
.0/).
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illion  Mexicans,  this  means  almost  900,000  people  sur-
ive  with  some  type  of  disability  or  sequel.  Worse,  after
 year  almost  half  of  them  survive  with  signiﬁcant  sequels
hat  affect  their  quality  of  life  and  their  capacity  to  perform
aily  life  activities  (Modiﬁed  Rankin  Scale  [mRS]  between  2
nd  5).7
As  if  that  were  not  enough,  the  economic  impact  is  noto-
ious  as  well.  Among  hospital  expenses,  studies,  treatments,
octors’  fees,  work  incapacities,  early  retirement,  rehabil-
tation  programs  and  more,  each  patient  surviving  stroke
early  spends  around  $25,000  dollars.4 This  is  of  course
ithout  taking  into  consideration  the  social  and  emotional
xpenses.
Stroke  prevalence  is  on  the  rise  worldwide,8 and  our
ountry  is  not  the  exception.9 In  Mexico  the  median  age  of
 ﬁrst  stroke  event  is  of  68  years  (ranges  52--84).7 Epidemi-
logy  studies  project  that  by  2050,  the  group  conformed  by
eople  aging  between  55  and  80  will  almost  triple,  to  28%.10
herefore,  by  that  year  there  will  be  more  than  2  million
troke  survivors;  1  in  every  60  Mexicans.
Even  though  there  have  been  many  attempts  to  develop
ew  stroke  cures,  a  thrombolytic  approach  with  tissue  plas-
inogen  activator  for  an  acute  ischemic  stroke  remains
s  the  only  approved  therapy.11 It  is  imperative  to  ﬁnd  or
evelop  a  new  treatment  to  enhance  recovery  and  restore,
t  least  partially,  the  lost  neurological  functions.
hysiopathology of stroke
tiology
troke  can  be  divided  into  ischemic  stroke,  constituting
5%  of  cases  (atherothrombotic,  cardioembolic,  small  vessel
isease),  and  hemorrhagic  stroke  (subarachnoid  hemor-
hage,  intraparenchymal  hemorrhage)  which  accounts  for
he  remainder  15%.12 The  later  one  has  an  overall  worse
rognosis.13 The  primary  risk  factors  for  stroke  include,  but
re  not  limited  to,  hypertension,  diabetes  mellitus,  smok-
ng,  dyslipidemia  and  atrial  ﬁbrillation.14
Cerebral  ischemia  is  graded  depending  on  the  cere-
ral  blood  ﬂow  (CBF;  which  would  normally  be  of
0--55  ml/100  g/min).  Anatomically,  stroke  lesions  can  be
ivided  into  an  ischemic  penumbra  (CBF  of  15  ml/100  g/ml),
ith  functionally  impaired  neurons,  though  still  reversible
ith  acute  stroke  therapy,  and  an  ischemic  central  core  (CBF
f  6  ml/100  g/ml)  with  irreversible  neuronal  death.15
atural  history
ack  of  energy  substrates  quickly  leads  to  dysfunction  of
nergy-dependant  ion  transport  pumps  and  depolarization
f  neurons  and  glia.16 This  depolarization  releases  excit-
tory  neurotransmitters,  primary  glutamate,  which  amplify
he  damage  by  the  release  of  free  radicals  and  interruption
f  the  electron  chain  transport.17 The  following  oxidative
tress  contributes  to  neuronal  death  by  disruption  of  the
ell  membrane.18 Apoptosis  also  mediates  many  of  the  lostPlease  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
eurons,  predominantly  in  the  penumbra  region  if  no  acute
reatment  is  installed.19
Afterwards,  astrocytes  concentrate  along  ischemic
esions,  and  produce  proteoglycans  to  form  a  glial  scar,
a
c
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hich  act  as  both  a  physical  and  biochemical  barrier  to
xonal  regeneration  and  sprouting,  limiting  the  reconnec-
ion  of  neural  circuits  and  contributing  to  many  of  the
ong-term  sequels  of  stroke.20,21
Most  important  for  the  matter  of  this  review  it
s  the  robust  inﬂammatory  reaction  following  cerebral
schemia.  Inﬂammatory  molecules  (e.g.  interleukin-1  [IL-1],
nterleukin-6  [IL-6]  and  tumoral  nectrotic  factor-alpha  [TNF-
])  are  predominantly  deleterious  in  the  early  phase  after
n  ischemic  stroke22 and  paradoxically  promote  brain  regen-
ration  and  neurovascular  remodeling  in  the  later  or  chronic
hases.23
Finally,  stroke  releases  many  chemotactic  molecules
e.g.  interleukin  8  [IL-8],  monocyte  chemoattractant
rotein-1  [MCP-1])  both  for  leucocytes  and  stem  cells.24
articularly  stromal-derived  factor  1a  (SDF1a)  is  released
y  activated  endothelial  cells  after  hypoxic  injuries,  and
ts  receptor  (CXC  chemokine  receptor-4  [CXCR4])  is  up-
egulated  as  well.25 They  both  acts  as  chemoattractants
hat  mediate  neural26 and  bone  marrow27 stem  cell  migra-
ion  to  injured  areas,  which  is  critical  for  stem  cell-based
herapies.
eurorestorative  therapies
fter  neuroprotection  (acute)  therapies  have  failed,  and
carring,  inﬂammation  and  edema  have  installed,  the
pproach  must  be  shifted  then  to  a  nuerorestorative  ther-
py  rather  than  on  preventing  the  extension  of  a  damage
hat  has  already  been  well  established.  This  type  of  therapy
ocuses  on  orchestrating  through  all  type  of  parenchymal
ells  (i.e.  neuroblasts,  immune  cells,  astrocytes,  oligoden-
rocytes  and  neurons),  the  enhancement  of  endogenous
eurogenesis,  angiogenesis,  axonal  sprouting  and  synapto-
enesis  in  affected  brain  tissue.28
Neurorestorative  therapies  include,  but  are  not  limited
o,  stem  cells.  There  are  also  ongoing  pharmacologi-
al  investigations29 and  other  type  of  treatments  such
s  electromagnetic  stimulation,  device-based  strategies,
epetitive  training  and  task-oriented  strategies.30 Reha-
ilitation  could  exploit  the  combination  of  functional
eorganization  and  adaptation  after  stroke.31 Of  all,  cur-
ently  only  constraint-induced  therapy  has  evidenced  some
ype  of  efﬁcacy.32
tem cells
ypes  of  stem  cells
ince  their  ﬁrst  descriptions  in  1963  by  Till  and  McCulloch,33
tem  cells  have  been  used  as  an  alternative  to  many  dis-
ases,  especially  those  without  any  other  treatment  options.
eurologic  conditions  have  not  been  the  exception.  In  fact
hey  represent  the  ﬁfth  most  common  cause  for  ongoing
linical  trials  based  just  on  mesenchymal  stem  cell  ther-
py  (after  bone,  heart,  gastrointestinal  and  autoimmune
isorders).34 Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
A  stem  cell  is  considered  as  such  when  two  properties
re  met:  capacity  for  long-term  self-renewal  without  senes-
ence  and  the  ability  to  differentiate  into  one  or  more
pecialized  cell  types.  Based  on  their  transdifferentiation
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Stem  cell  therapy  for  stroke  
spectrum  stem  cells  are  classiﬁed  as  totipotent  if  they  can
form  any  cell  in  the  body  (including  placental  cells),  as
pluripotent  if  they  are  able  to  divide  into  any  cell  of  the
three  germ-lines  of  early  embryogenesis,  and  as  multipo-
tent  if  they  are  already  committed  to  only  one  germ-line
(e.g.  most  bone  marrow  stem  cells  can  only  differentiate
into  mesoderm  derived  cells).35
Stem  cells  are  also  classiﬁed  based  on  their  origin
as  embryonic  or  adult  type.  Embryonic  stem  cells  (ESC)
are  pluripotent  cells  that  are  obtained  by  manipulating
embryos  before  implantation.36 Adult  (somatic)  stem  cells
are  multipotent  (or  pluripotent)  cells  obtained  from  mature
differentiated  tissues  such  as  bone  marrow,  umbilical  cord,
human  olfactory  mucosa,  fat  tissue  and  brain.37
Finally,  another  type  of  stem  cell  is  the  induced  pluripo-
tent  stem  cells  (iPSC).  In  this  technique,  differentiated
mouse  ﬁbroblasts  are  reprogrammed  to  an  embryonic-like
state  (pluripotency)  by  transfer  of  nuclear  contents  into
oocytes  or  by  fusion  with  embryonic  stem  cells.38
Neural  stem  cell
Contrary  to  old  assumptions,  evidence  of  neurogenesis  in
the  adult  human  brain  has  been  demonstrated.39 Neural
stem  cells  (NSC)  are  a  multipotent  variant  of  stem  cells
present  in  the  brain.40 These  cells  are  located  in  the  sub-
ventricular  zone  (SVZ)  of  the  third  ventricle41 and  in  the
subgranular  zone  (SGZ)  of  dentate  gyrus,42 and  respond  to
brain  insults  that  cause  neuronal  death  such  as  stroke,43
Huntington’s  disease,44 and  Alzheimer’s  disease.45 NSC  not
only  proliferate  but  also  migrate  to  areas  of  lesion  even  in
elderly  patients.46 NSC  can  be  cultured  in  vitro  for  stem  cell
therapies,  and  even  if  administered  intravenously,  have  the
capacity  to  migrate  into  ischemic  areas.47
It  is  been  documented  that  after  a  stroke  NSC  expand
and  mature  into  well  differentiated  neurons  and  integrate
functionally  into  neuronal  circuits.48 After  a  stroke,  the
brain’s  environment  holds  a  rise  in  many  growth  factors  that
induce  changes  in  NSC’s  mitotic  cell  cycle  such  as  reduc-
tion  of  G1  phase49 which  boosts  mitotic  rate  up  to  a  12-fold
increase  in  number42 as  well  as  activation  of  phosphatidylin-
ositol  3-kinases-Akt  signaling  pathway  which  enhances  cell
survival,  proliferation,  differentiation  and  migration.50,51
Stroke  also  activates  many  genes  involved  in  neurogen-
esis  during  embryonic  development,  especially  those  of
transforming  growth  factor-beta  [TGF-] superfamily  (bone
morphogenic  protein  8  [BMP2],  bone  morphogenetic  protein
type  1  receptors  [BMPR1]  and  growth  differentiation  factor
2  [GDF2]).52 These  newly  formed  neurons  differentiate  into
the  phenotype  of  most  of  the  neurons  that  were  lost  dur-
ing  ischemia,  in  an  attempt  to  regenerate  lost  circuits  and
recover  lost  functions.46
Discouragingly,  one  of  the  setbacks  is  their  slim  capac-
ity  to  migrate  into  areas  of  the  cortex  where  higher  mental
functions  lie.46 What  is  more,  after  a  couple  of  weeks  80%
of  these  newly  formed  neurons  die  and  actually  just  0.2%  of
dead  tissue  is  replaced.46 We  hypothesize  that  if  the  per-Please  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
centage  of  incorporated  renewed  cells  could  be  increased
somehow,  (e.g.  neurotrophic,  or  angiogenic  factors)  restora-
tion  of  neurological  functions  would  be  much  greater  as
well.
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one  marrow  stem  cells
one  marrow  stem  cells  (BMSC)  are  an  array  of  different
ype  of  multipotent  and  pluripotent  cells  homed  in  the
pongy  tissue  of  almost  all  bones.  Two  basic  lineages  prevail:
ematopoietic  stem  cells  (HSC,  PBSC  if  obtained  peripher-
lly)  and  mesenchymal  stem  cells  (MSC).  HCS  give  rise  to  all
he  type  of  blood  cells  and  are  typically  CD34+,  CD133+  and
egative  for  all  markers  of  differentiation  or  further  lineage
ommitment  (CD13−, CD71−, CD19−, CD61−).53 MSC  lie  on
he  stroma  of  the  bone  marrow,  and  contrary  to  HSC,  they
an  differentiate  into  a broader  variety  of  cell  types,  such
s  osteoblasts,  chondrocytes,  myocytes  and  adipocytes  and
ven  neurons.54 MSC  are  usually  CD34-.55
BMSC  actually  have  limited  cellular  differentiation  abil-
ty  in  comparison  to  other  type  of  stem  cells;  evidence
uggests  instead  that  the  beneﬁcial  properties  are  due  to
mmunomodulatory  mechanisms,  as  they  migrate  to  sites  of
nﬂammation  (by  the  mechanisms  explained  before)56 and
ecrete  many  bioactive  molecules.57 This  is  supported  by
he  fact  that  PBSC  are  also  used  with  efﬁcacy  in  the  autolo-
ous  therapy  of  non-hematopoietic  tissues  like  neurons,58
keletal  muscle59 and  heart.60 In  multiple  sclerosis  and
mniotrophic  lateral  sclerosis  for  instance,  immunomodu-
atory  effects  and  improvements  were  observed  just  24  h
fter  intrathecal  delivery  of  MSC,  which  would  be  an  irra-
ional  time  frame  for  differentiation  and  rather  backs  up
he  hypothesis  of  a  bystander  effect  instead.61 Furthermore,
ix  months  later,  evidence  of  integration  or  even  survival
f  these  cells  was  very  poor.62 In  an  animal  model,  CD34+
ells  (HSC)  were  tracked  by  magnetic  resonance,  where  they
rove  they  migrate  to  lesion  sites  but  just  persisted  for  about
 to  4  weeks.63
Even  though  there  is  a very  low  rate  of  transdifferen-
iation  into  neurons,  there  is  still  clinical  recovery,  motor
voked  potential  improvements,  as  well  as  reconstruction  of
he  ischemic  tissue.64 As  stated  before,  the  beneﬁts  of  BMSC
ould  be  by  enhancing  endogenous  neurogenesis  rather  than
ellular  lineage  reprogramming.  The  mechanisms  involved
ppear  to  be  paracrine  secretion  of  bioactive  molecules  and
pgrade  regulation  of  receptors  that  reinforce  and  augment
he  natural  recovery  processes  implemented  by  the  brain;
ubsequently  increasing  the  number  of  new  functional  neu-
ons  derived  from  endogenous  neuroblasts.
It  has  been  proved  that  exogenous  administration
f  brain-derived  neurotrophic  factor  (BDNF)  stimulates
euroegenesis,65 therefore,  endogenous  secretion  of  BDNF
nd  similar  trophic  factors  by  stem  cells  would  aid  in  such
urposes.  BMSC  increases  concentration  of  SDF1a  as  well  as
xpression  of  the  SDF-1  receptor,  CXCR4  in  the  perischemic
rea.66 There  is  also  promotion  of  basic  ﬁbroblast  growth
actor  (bFGF)  and  other  trophic  factor  like  -nerve  growth
actor  (-NGF)67 which  would  not  only  promote  prolifera-
ion,  but  will  reduce  apoptosis  as  well.68
BMSC  increase  the  number  of  oligodendrocyte  progeni-
ors  and  increase  axonal  density  around  the  ischemic  lesion,
xtending  and  orienting  axons  parallel  to  the  boundary  of
he  penumbra.69 They  do  this  by  reducing  expression  of Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
xonal  growth  inhibitory  proteins,  such  as  reticulon  and  neu-
ocan,  enabling  axonal  and  neurite  outgrowth.70
MSC  also  share  the  properties  of  secreting  many
rophic  factors  (BDNF,  SDF-1,  NGF,  bFGF,  and  VEGF)  and
 IN+ModelR
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romoting  neurogenesis71 with  the  added  beneﬁt  of  a
reater  potential  than  regular  HSC  to  transdifferentiate  into
eurons  themselves.72,73 MSCs  carry  the  beneﬁt  of  being
eadily  obtained  from  bone  marrow  and  easily  expanded  by
ulture  in  vitro,  though  this  involves  a  time  frame  of  4  to  5
eeks  before  being  delivered  back  to  patients.74
MSC  are  pretty  safe.  Because  of  their  low  major  histo-
ompatibility  complex  proteins  they  are  considered  immune
rivileged  and  cause  no  immunogenicity,  neither  acute  or
hronic.75 In  a  recent  meta-analysis,  there  was  no  asso-
iation  between  MSC  and  neoplastic  potential,  infection,
mbolism  or  zoonosis;  in  fact  the  only  side  effect  was  tran-
ient  low-grade  fever  (OR:  16.82).76
Angiogenesis  also  plays  a  critical  role  in  functional  recov-
ry.  As  in  neurogenesis,  angiogenesis  is  induced  by  several
rowth  factors  present  in  the  penumbra  3  to  4  days  after  a
troke.77 It  is  so  relevant,  that  patients  who  have  a  high  den-
ity  of  blood  vessels  after  stroke  survive  longer  than  those
ho  do  not.78 Animal  models  with  denser  vascularization
ave  a  better  functional  outcome  as  well.79 This  density  is
etermined  by  the  presence  of  vascular  growth  factors,  for
here  is  a  correlation  between  greater  concentration  gra-
ients  of  them  and  increased  blood  vessel  neoformation.80
nterestingly,  neurogenesis  actually  enhances  symbiotically
ngiogenesis  by  secreting  the  same  factors.81,82 Given  that
MSC  up-regulate  expression  and  paracrine  secretion  of
ngiogenic  growth  factors  such  as  vascular  endothelial
rowth  factor  (VEGF)  and  its  receptor  (VEGFR2)  as  well  as
ngiopoeitins  1  and  2  and  their  receptor  (TIE-1  and  TIE-2),83
t  is  hypothesized  that  they  would  magnify  the  beneﬁ-
ial  properties  of  neurogenesis  and  angiogenesis  along  with
mproving  clinical  outcomes  and  survival  rate.84
Deciding  which  is  better  among  HSC,  PBSC  or  MSC  is  still
nachieved.  The  only  human  clinical  trial  comparing  HSC  and
xpanded  MSC  found  out  that  patients  had  better  clinical
utcomes  (Barthel  Index  [BI])  with  HSC.85
ther  type  of  stem  cells
esides  BMSC  and  NSC,  other  type  of  stem  cells  may  be  used
or  stroke  and  other  diseases.  Pluripotent  stem  cells  (e.g.
SC),  with  a  wider  transdifferentiation  spectrum,  have  the
heoretical  advantage  over  multipotent  cells  in  its  use  for
egenerative  medicine;  however,  the  downside  is  the  accom-
anying  increased  risk  of  developing  malignancies  as  well.86
n  addition  to  this  ESC  bear  ethical,  technical  and  legal  issues
egarding  the  use  of  human  embryos.87
As  promising  as  they  might  be,  iPCS  have  not  been
pproved  yet  to  be  used  in  any  clinical  trial  involving  humans
s  concerns  involving  tumorigenicity  abound.88 iPSC  dis-
lay  more  genetic  and  epigenetic  abnormalities  than  other
ype  of  stem  cells.89 Actually,  their  capability  of  developing
luripotent  malignancies,  such  as  teratoma  surpasses  that
f  ESC.90
tem cell therapy for strokePlease  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
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esign  of  clinical  trial
he  ﬁrst  attempt  to  treat  stroke  using  stem  cells  was  more
han  15  years  ago.91 Hitherto  there  is  still  no  optimum  model
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or  a clinical  trial.  With  stroke  being  so  diverse  and  many
spects  of  stem  cell  therapy  still  unexplored,  many  variables
ave  to  be  thrown  into  the  equation.  We  will  discuss  each
f  these  variables  separately.
election  of  patient
troke  lesion  sizes  and  locations  are  broadly  heterogeneous
n  addition  to  normal  neuroanatomical  variations  among
ndividuals.  Besides,  depending  on  the  etiology,  stroke  out-
omes  and  prognosis  vary  hugely  as  well.9 Therefore,  stroke
utcomes  are  extraordinarily  diverse  among  patients;  even
ithout  intervention,  most  patients  exhibit  limited  spon-
aneous  recovery,  though  a  subgroup  will  remain  severely
mpaired.92 On  the  other  hand,  even  with  effective  throm-
olysis  most  patients  will  still  have  neurological  deﬁcits.93
So  without  a  control  or  a  placebo  group,  it  is  difﬁcult
o  distinguish  whether  improvements  are  stem  cell  therapy-
ased  or  just  the  natural  history  of  the  disease.  Ideally,  and
pecially  to  address  efﬁcacy,  inclusion  criteria  should  be  the
ost  homogenously  possible  (in  age,  etiology  and  comor-
idities)  to  avoid  confounding  biases,  even  if  this  comes  at
he  cost  of  shortening  the  number  of  patients.94
Selecting  patients  with  little  to  no  predicted  natural
ecovery  may  highlight  the  beneﬁts  of  cell  therapy,  though
his  represents  an  obstacle  given  that  most  patients  do
ot  exhibit  explicit  recovery  until  3--6  months  after  stroke,
 time  frame  which  limit  most  of  the  clinical  trials  that
dvocate  for  administration  of  stem  cells  much  earlier.95
he  expected  recovery  can  be  anticipated  early  (within
ays  after  stroke)  by  the  use  of  specialized  techniques  of
euroimaging  (e.g.  ﬁber  numbers  asymmetry)96 and  neuro-
hysiological  assessments  (e.g.  motor-evoked  potentials),97
hich  would  help  us  select  patients  with  the  worst  prog-
oses  to  treat  them  in  acute  phases;  though  these  are  not
et  used  routinely.28
Double  blinding  enhances  statistical  power  to  the  clinical
rial,  but  this  may  not  be  ﬁtting  for  the  more  invasive  inter-
entions,  such  as  intrathecal  or  intracerebral  approaches.
osage
 consensus  regarding  dosage  has  not  been  met.  Nonethe-
ess,  there  is  clear  relation  between  more  cells  administered
nd  better  outcomes.67,98 Therefore,  given  the  safety  pro-
le  of  autologous  stem  cells,  efforts  to  recollect  the  highest
umber  cells  possible  must  be  done.  This  of  course  would  not
pply  for  allogenic  stem  cells,  where  the  risk  of  graft  ver-
us  host  disease  and  rejection  are  much  greater  with  higher
oses.99
Another  matter  regarding  dosage  concerns  the  use  of
ranulocyte  colony  stimulating  factor  (GCS-F)  either  as  an
ttempt  to  increase  number  of  available  stem  cells  for
ollection,  or  even  as  a  mean  of  treatment  itself.  GCS-
,  as  an  up-regulator  of  hematopoiesis  has  demonstrated
o  increase  exponentially  the  number  of  PBSC  and  could
heoretically  work  as  if  these  have  been  exogenously  admin- Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
stered  (i.e.  migrate  to  penumbra  and  enhance  recovery).100
afety  of  GCS-F  has  been  established  in  hyperacute  stages  of
troke  (24--48  h  after  onset),101 which  would  carry  an  enor-
ous  advantage  over  stem  cells,  given  that  these  would  be
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Stem  cell  therapy  for  stroke  
difﬁcult  to  have  at  hand  that  much  early,  especially  in
unstable  patients.  Although  the  trend  is  toward  better
outcomes,102 efﬁcacy  of  GCS-F  has  not  been  thoroughly
proven  and  is  yet  to  be  determined  if  they  could  be  used
as  an  alternative  therapy  alone  or  even  as  a  coadjuvant  of
stem  cell  therapy.
Time  of  intervention
If  any  natural  recovery  is  going  to  happen  is  not  seen  until
around  3--6  months  after  the  onset  of  stroke,103 and  wait-
ing  that  much  could  limit  many  of  the  immunomodulatory
effects  of  stem  cells.  Besides  most  data  points  toward  bet-
ter  functional  outcomes  if  stem  cells  are  administered  much
earlier.104 In  one  animal  model,  only  the  rats  receiving
BMSC  intravenously  7  days  after  artery  occlusion  exhibited
decreased  ischemic  lesion  volume  in  contrast  to  those  who
received  them  at  days  14  and  28.  Interestingly  tough,  all
three  groups  displayed  clinically  signiﬁcant  better  functional
outcomes  compared  to  the  placebo  group,  suggesting  that  1
month  after  stroke  might  be  a  suitable  time-frame.66,105
Nevertheless,  patients  with  much  more  chronic  stroke
still  exhibit  improvements  in  neurological  functions.106
Considering  the  importance  of  inﬂammatory  chemotaxis  for
stem  cell  therapy,  this  hints  to  the  hypothesis  that  stroke
constitutes  a  state  of  very  chronic  state  of  inﬂammation.
Therefore,  independent  of  the  time  of  administration,  stem
cells  will  always  migrate  to  some  degree  to  the  areas  of
lesion  or  even  to  the  scarring  tissue.  Evidence  suggests
that  stem  cells  in  early  stages  work  as  anti-inﬂammatory
molecules  and  in  chronic  stages  aid  in  endogenous  recovery
and  neurorestoration.23
Administration  time  should  also  be  decided  depending  on
the  feasibility  of  the  route  of  administration  as  patients  with
hyperacute  stroke  (<72  h)  are  usually  neurologically  unstable
and  cannot  tolerate  invasive  procedures.107
Route  of  administration
The  American  Stroke  Association  in  its  recommendation  for
future  stem  cell  research  states  that  the  safest  and  most
effective  route  of  cell  delivery  should  be  deﬁned  using
preclinical  trials.95 There  are  four  major  possible  routes:
intravenous  (IV),  intra-arterial  (IA),  intrathecal  (IT)  and
intracerebral  (IC).108,109 (See  Fig.  1)
It  is  clear  due  to  the  many  clinical  trials,  that  the  IV
route  is  the  safest  and  most  feasible  for  administrating  stem
cells.74,85,110,111 Unfortunately,  the  most  effective  route  is
yet  to  be  determined.
The  basis  for  peripheral  and  non-invasive  approaches  (IV
and  IA)  is  the  phenomenon  of  the  selective  permeability  of
the  blood-brain  barrier  (BBB).  After  a  brain  insult,  specially
a  hypoxic  one,  the  tight  junctions  between  the  endothelial
cells  of  the  capillaries  loosen  up,  therefore  increasing  its
permeability  and  allowing  income  of  many  molecules  includ-
ing  inﬂammatory  cells.112 This  breakdown  may  even  persist
for  weeks  or  even  months  after  the  original  insult,  justi-Please  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
fying  stem  cell  therapies  in  chronic  stages.113 Despite  this,
it  remains  unclear  whether  systemically  infused  stem  cells
are  able  to  cross  in  a  signiﬁcant  extent  the  BBB  under  both
normal  and  pathological  conditions.114
o
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IA  administration  of  stem  cells  theoretically  increments
he  number  of  cells  delivered  to  the  lesion  area  in  compar-
son  to  IV;  yet  stem  cells  through  these  route,  especially
n  high  doses,  may  cause  recurrent  stroke.115 On  the  other
and,  another  study  that  displayed  safety  of  IA  infusion  in
 window  time  of  3--7  days,  though  this  was  just  made  in
 patients.116 Even  though  considered  not  as  an  invasive
pproach  as  others,  safety  of  IA  route  must  be  reevaluated
n  larger  clinical  trials.
Another  major  pitfall  of  peripheral  routes  is  the  sub-
tantial  loss  of  cells  in  other  parts  of  the  body.117 When
njected  IV,  stem  cells  are  distributed  all  around  the  body
nd  are  homed  in  other  organs  like  the  liver,  kidney,  lungs
nd  spleen.118 Nonetheless,  perhaps  it  isn’t  strictly  neces-
ary  for  the  cells  to  be  homed  in  the  penumbra  area  for  them
o  perform  their  anti-inﬂammatory  properties.  Some  types
f  stem  cells  may  not  even  enter  the  central  nervous  sys-
em  and  may  instead  promote  stroke  recovery  by  acting  on
eripheral  organs.28 Whether  this  contributes  signiﬁcantly
o  clinical  improvements  remains  an  interrogatory.
In  one  animal  model  of  human  umbilical  cord  blood-
erived  MSC,119 it  was  observed  that  there  was  a  major
igration  and  concentration  of  stem  cells  in  the  areas  of
ypoxia  after  IT  administration  compared  to  an  IV  approach,
s  well  as  a  longer  survival  period  of  these  giving  a  great
dvantage  to  this  approach.  Additionally,  IT  administration
f  stem  cells  for  other  neurological  disorders  has  been  found
o  be  safe  and  well  tolerated;  with  the  main  side  effects
eing  headache  and  transient  low-grade  fever.120--122 Never-
heless,  some  serious  adverse  effects  have  been  described
s  well.  Case  reports  of  inﬂammatory  hypertrophic  cauda
quine,123 demyelinating  encephalomyelitis,124 and  spinal
yoclonus125 following  intrathecal  injection  of  stem  cells
combination  of  ESC,  MSC  and  HSC)  for  different  diseases
ave  been  published.  However,  these  interventions  were
erformed  in  stem  cell  therapy  clinics,  with  no  more  infor-
ation  given.
When  implanted  IC  via  stereotaxis,  grafted  MSC  cells
re  visualized  prominently  just  24  h  after  implantation  and
re  homed  almost  exclusively  in  the  affected  site,  posi-
ioning  this  route  as  the  most  effective  in  terms  of  cell
oncentration.  Though  as  with  animal  models,  evidence  of
hese  cells  by  neuroimaging  (hypointensity  on  T2)  became
maller  gradually  in  the  following  4  weeks  until  ﬁnally
issapearing.64 One  must  weight  the  risk  and  beneﬁts  when
onsidering  this  invasive  approach,  particularly  when  using
MSC  where  beneﬁts  may  just  be  temporal.  Stereotaxis  may
e  more  justiﬁable  if  using  exogenous  NSC  where  there  is  a
easonable  expectation  of  functional  engraftment  and  a  per-
anent  incorporation  to  neural  circuits.126 One  must  take
nto  account  that  IC  administration  is  unfeasible  in  acute
nd  in  unstable  patients.
andomized  clinical  trials
o  our  knowledge,  there  are  only  7  randomized  clinical  trials
ublished  that  have  used  stem  cell  therapy  for  the  treatment Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
f  acute  stroke  (Table  1).
The  ﬁrst  ever  randomized  clinical  trial74 used  ex  vivo
ultured  autologous  MSC  and  then  infused  them  IV  twice
weeks  4  and  8).  All  patients  from  the  MSC  group  (n  =  5)  had
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Table  1  Randomized  clinical  trials.
Title  Country  Year  Type  of
stroke
GCS-F  Type  of  Cell  Route  of
administration
N  (cases)  Results
1  Intravenous  autologous  bone
marrow  mononuclear  stem  cell
therapy  for  ischemic  stroke
India  2014  Acute  (10  d
to  28  d)
No  HSC  (3  ×  106
CD34+)
Intravenous  120  (60)  No  changes
2 Intracerebral  implantation  of
autologous  peripheral  blood
stem  cells  in  stroke  patients:  a
randomized  phase  II  study
Taiwan  2014  Chronic  (6  m
to  5  y)
Yes  PBSC
(3--8  ×  106
CD34+)
Intracerebral  30  (15)  Signiﬁcant
improvements
3 Intra-arterial  bone  marrow
mononuclear  cells  in  ischemic
stroke:  a  pilot  clinical  trial
Spain  2012  Acute  (5  d
to  9  d)
No  HSC
(1.5  ×  106
CD34+))
Intra-arterial  20  (10)  Non-
signiﬁcant
improvements
4 Stem  cell  therapy:  a  clinical
trial  of  stroke
India  2012  Chronic  (3  m
to  24  m)
Noa HSC  &  MSC
(5  ×  106)b
Intravenous  40  (20)  Signiﬁcant
improvements
5 A  long-term  follow  up  study  of
intravenous  autologous
mesenchymal  stem  cell
transplantation  in  patients
with  ischemic  stroke
South
Korea
2010  Acute  (4  wk)  Noa MSC
(1  ×  108)
Intravenous  52  (16)  Signiﬁcant
improvements
6 Autologous  mesenchymal  stem
cell  transplantation  in  stroke
patients
South
Korea
2005  Acute  (4  wk
to  5  wk)
Noa MSC
(1  ×  108)
Intravenous  30  (5)  Signiﬁcant
improvements
7 Neurotransplantation  for
patients  with  subcortical  motor
stroke:  a  phase  2  randomized
trial
USA  2005  Chronic  (1
yr  to  6  yr)
No  Human
Neuronal
Cells  (LBS®)
5--10  ×  106
Intracerebral  18  (4)  Non-
signiﬁcant
improvements
Abbreviations: GCS-F, Granulocyte colony stimulating factor; d, days; wk, weeks; m, months; yr, years; HSC, Hematopoietic stem cells; PBSC, Peripheral blood stem cells, MSC, Mesenchymal
stem cells, LBS, Layton BioScience.
a MSC were expanded in vitro.
b For both CD34+ & MSC.
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Routes of administration
Intracerebral
Intra-arterial
IntravenousIntrathecal
• Cells injected
directly into infarct
(highest
concentration of
cells)
• Increases
concentration of
cells
• Cells have to
cross BBB
• Simple
• Safe
• Fast
• Reduced
concentration of 
cells at damaged
site
• Cells have to
cross BBB
• May cause
recurrent stroke
• Invasive
• Avoids BBB
• Higher
concentration of
cells
• Invasive
• Unfeasible in
acute strokes
• Cells may deposit
caudally
• Technically
challenging
• Unfeasible in
unstable patients
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cerebral  infarcts  that  involved  the  middle  cerebral  artery
territory.  They  reported  signiﬁcant  improvements  in  BI  (3
and  6  months)  and  mRS  (3  months).  One  year  outcomes
were  not  signiﬁcant.  The  main  limitations  of  this  study  are
the  small  treatment  group  and  a  short  follow-up  period.  A
similar  approach  was  used  by  the  same  authors  but  with  a
larger  population  (MSC  group  n  =  16  and  control  group  n  =  36)
and  a  longer  follow-up  (5  years).110 Signiﬁcant  improvement
of  the  mRS  were  reported  in  the  MSC  group  (p  =  0.046),  in
contrast  with  the  control  group  (p  =  0.257).  The  mortality
rate  in  the  MSC  group  was  lower  than  in  the  control  group
(Log  rank:  p  =  0.059),  and  there  was  no  difference  in  comor-
bidites  during  the  follow-up  period.  Notably,  there  was  also
a  correlation  between  higher  levels  of  the  SDF-1a  and  clin-
ical  improvements,  emphasizing  the  crucial  role  played  by
chemoattractants  in  this  type  of  therapies.
An  IC  approach  has  been  used  twice.  Kondziolka  et  al.
implanted  stereotactically  5  or  10  million  allogenic  neuronal
cells  cultivated  from  human  embryonic  carcinoma-derived
cells  (LBS®)  to  14  patients  with  chronic  stroke.104 They
demonstrated  safety  of  the  procedure,  as  no  serious  adverse
effects  occurred  after  a  5  year  follow-up.  Non-signiﬁcant
improvements  were  found,  especially  in  those  having
an  ischemic  stroke.  Regarding  neuropsychological  testing,
marked  improvement  was  seen,127 as  well  as  improved  F-
ﬂuorodeoxyglucose  (FDG)  uptake  in  hypoxic  areas.  The  other
clinical  trial  also  used  stereotaxis  in  15  chronic  strokePlease  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
patients,  implanting  3--8  million  CD34+  cells  after  stimu-
lated  (with  G-CSF)  PBSC  where  recollected  by  apheresis.64
The  treated  group  showed  a  signiﬁcant  improvement  in  the
National  Institute  of  Health  Stroke  Scale  (NIHSS),  European
F
A
mtration  of  stem  cells  for  stroke.
troke  scale  (ESS)  and  ESS  motor  subscale  (EMS).  Further,
here  were  reductions  in  ﬁber  number  asymmetry  of  the
amaged  corticospinal  tracts  as  well  as  restoration  of  motor
voked  potentials  response,  both  correlating  with  better
unctional  outcomes.  These  changes  were  not  observed  in
he  control  group.  Safety  end-points  were  acknowledged.
The  only  IA  clinical  trial  conducted  showed  functional
mprovements,  though  these  were  not  signiﬁcant.67 Ten
atients  were  injected  with  1.5  ×  108 autologous  HSC
etween  5  and  9  days  after  ischemic  stroke.  No  serious
dverse  events,  stroke  recurrence  (clinical  or  by  image),  nor
umor  formation  were  observed  during  the  follow-up  period
6  months).  Interestingly,  there  was  a  trend  toward  better
linical  outcome  when  higher  numbers  of  CD34+  cells  were
njected.
The  most  recent,  and  by  far,  the  larger  clinical  trial
erformed  (60  cases  and  60  controls)  infused  intravenously
.9  ×  106 CD34+  obtained  by  HSC  in  subacute  stroke  patients
median  of  18.5  days  after  stroke).111 Even  though  safety  was
et,  no  changes  were  observed  as  to  functional  improve-
ents.  This  contrasts  with  results  obtained  by  the  same
esearch  group  a few  years  back,  where  they  used  either
SC  or  MSC  in  chronic  patients  (n  treated  =  20),  and  found
tatically  signiﬁcant  improvements  in  BI,  as  well  as  increased
umber  of  cluster  activation  in  motor  cortex  area,  suggest-
ng  neuroplasticity.85 Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
ollow-up
 biological  marker  that  can  assess  selectively  improve-
ents  of  neurological  functions  after  an  ischemic  or
 IN+ModelR
8
h
t
T
a
n
N
m
r
s
o
l
r
r
c
e
a
F
T
h
r
l
T
b
l
i
r
c
a
a
e
t
b
a
n
c
a
n
C
T
F
N
D
T
RARTICLEMU-85; No. of Pages 12
 
emorrhagic  event  is  in  great  need,94 but  that  as  it  may,
here  is  currently  no  validated  marker  for  such  purposes.128
herefore,  we  must  rely  on  other  tools  such  as  clinical  scales
nd  neuroimaging.
On  this  matter,  more  extensive,  objective  and  speciﬁc
eurological  outcomes  that  measure  beyond  the  classical
IHSS,  BI,  mRS,  ESS,  or  EMS  need  to  be  developed  and  imple-
ented  for  restorative  treatments.129
Magnetic  resonance  imaging  (MRI)  is  an  invaluable
esource  to  gauge  more  objectively  improvements  after
tem  cell  therapy.  The  focus  should  not  be  on  the  reduction
f  stroke  volume  size  or  edema,  as  these  do  not  trans-
ate  directly  into  better  functional  outcomes,  and  should
emain  then  as  secondary  endpoints.28 Rather,  restructu-
ing  of  white  matter  tracts,  neurogenesis  and  angiogenesis
an  be  better  used  as  to  monitor  recovery,  which  can  be
valuated  through  more  sensitive  MRI  techniques  such  as
nisotropy130,131 and  magnetically  labeled  cells.132
uture  & perspective
he  feasibility  and  safety  of  stem  cells  in  stroke  patients
ave  both  been  roundly  conﬁrmed.  But  in  spite  of  the
emarkable  improvements  observed  in  animal  models,  trans-
ation  to  clinical  scenarios  has  not  been  achieved  so  far.
he  overall  results  of  stem  cell  therapy  for  stroke  have
een  inconclusive,  at  best.  Yet,  the  tendency  seems  to
ean  toward  better  functional  outcomes.  Many  unsolved
ssues  remain  regarding  timing,  dosage,  type  of  cell,  and
oute  of  administration.  And  until  these  are  not  addressed,
onclusions  concerning  efﬁcacy  should  not  be  given  at
ll.  Therefore,  larger  double-blind  randomized  clinical  tri-
ls  with  homogenous  selection  criteria  and  domain-speciﬁc
nd  points  are  strongly  encouraged  to  clarify  this  mat-
er.  Certainly,  a  predictive  marker  of  which  patients  would
eneﬁt  the  most  from  cell  therapy  would  be  of  immense
id.
Given  the  magnitude  of  the  physical,  emotional  and  eco-
omic  burden  that  stroke  survivors  have  to  endure,  and  its
olossal  impact  on  society  as  a  whole,  efforts  to  ﬁnd  the
ppropriate  stem  cell  therapy  for  neurorestoration  should
ot  surcease  but  be  encouraged.
onﬂicts of interest
he  authors  have  no  conﬂict  of  interest  to  declare.
unding
o  ﬁnancial  support  was  provided.
isclosure statement
he  authors  have  nothing  to  disclose.Please  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
eferences
1. Principales causas de mortalidad por residencia habitual,
grupos de edad y sexo del fallecido. Instituto Nacional de PRESS
D.M.  Martínez-Garza  et  al.
Estadística y Geografía; 2014. http://www.inegi.org.mx/
est/contenidos/proyectos/registros/vitales/mortalidad/
tabulados/ConsultaMortalidad.asp
2. Góngora-Rivera F. Perspective on stroke in Mexico.
Med Univ. 2016;17:184--7, http://dx.doi.org/10.1016/
j.rmu.2015.04.001.
3. Norrving B. The global burden of stroke and need for
a continuum of care. Neurology. 2013;80 Suppl 2:5--12,
http://dx.doi.org/10.1212/WNL.0b013e3182762397.
4. Ruiz JL. Costos de la enfermedad vascular cerebral
en México. AMEVASC; 2014. http://amevasc.mx/costo-de-
la-enfermedad-vascular-cerebral-en-mexico/
5. Teasell R. Long-term sequelae of stroke. Can Fam Phys.
1992;38:381--8.
6. Cantu-Brito C, Majersik JJ, Sánchez BN, et al. Door-to-
door capture of incident and prevalent stroke cases in
Durango, Mexico: the Brain Attack Surveillance in Durango
Study. Stroke. 2011;42:601--6, http://dx.doi.org/10.1161/
STROKEAHA.110.592592.
7. Cantú-Brito C, Ruiz-Sandoval JL, Murillo-Bonilla LM, et al.
Acute care and one-year outcome of Mexican patients with
ﬁrst-ever acute ischemic stroke: the PREMIER study. Rev Neu-
rol. 2010;51:641--9.
8. Donnan GA, Fisher M, Macleod M, et al. Stroke
Lancet. 2008;371:1612--23, http://dx.doi.org/10.1016/
S0140-6736(08)60694-7.
9. Marquez-Romero JM, Arauz A, Góngora-Rivera F, et al. The
burden of stroke in México. Int J Stroke. 2015;10:251--2,
http://dx.doi.org/10.1111/ijs.12189.
10. Proyecciones de la población 2010--2050. Consejo Nacional
de la Población; 2010. http://www.conapo.gob.mx/
es/CONAPO/Proyecciones
11. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for
ischemic stroke: two decades of success and failure. NeuroRx.
2004;1:36--45, http://dx.doi.org/10.1602/neurorx.1.1.36.
12. Morales-Vidal S. Stroke pathophysiology. Futur Med.
2001:6--20, http://dx.doi.org/10.2217/EBO.12.443.
13. Ruiz-Sandoval JL, Cantú C, Chiquete E, et al. Aneurysmal
subarachnoid hemorrhage in a Mexican multicenter registry
of cerebrovascular disease: the RENAMEVASC Study. J Stroke
Cerebrovasc Dis. 2009;18:48--55, http://dx.doi.org/10.1016/
j.jstrokecerebrovasdis.2008.09.019.
14. Nayak SD, Sarma PS, Radhakrishnan K. Incidence, types,
risk factors, and outcome of stroke in a developing
country. Stroke. 2009;40:1212--9, http://dx.doi.org/10.1161/
STROKEAHA.108.531293.
15. Yoo AJ, Copen WA,  Gonza RG. Cerebral blood ﬂow thresholds
for tissue infarction in patients with acute ischemic stroke
treated with intra-arterial revascularization therapy depend
on timing of reperfusion. Am J Neuroradiol. 2011;32:846--51,
http://dx.doi.org/10.3174/ajnr.A2415.
16. Lloyd HGE, National A. The early events of oxygen and glu-
cose deprivation: setting the scene for neuronal death? Trends
Neurosci. 1994;17:251--7.
17. Mehta SL, Manhas N, Raghubir R. Molecular targets in
cerebral ischemia for developing novel therapeutics.
Brain Res. 2007;54:34--66, http://dx.doi.org/10.1016/
j.brainresrev.2006.11.003.
18. Koehler C. Oxygen radical mechanisms of brain injury following
ischemia and reperfusion. J Appl Physiol. 1991:1185--95.
19. Broughton BRS, Reutens DC, Sobey CG. Apoptotic mech-
anisms after cerebral ischemia. Stroke. 2009;40:331--9,
http://dx.doi.org/10.1161/STROKEAHA.108.531632.
20. Carmichael ST. Cellular and molecular mechanisms of Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
neural repair after stroke: making waves. Ann Neurol.
2006;59:735--42, http://dx.doi.org/10.1002/ana.20845.
21. Stoll G, Jander S, Schroeter M. Inﬂammation and glial
responses in ischemic brain lesions. Prog Neurobiol.
 IN+Model ARTICLERMU-85; No. of Pages 12
Stem  cell  therapy  for  stroke  
1998;56:149--71, http://dx.doi.org/10.1016/S0301-0082(98)
00034-3.
22. Jin R, Yang G, Li G. Inﬂammatory mechanisms in
ischemic stroke: role of inﬂammatory cells. J Leukoc
Biol. 2010;87(May):779--89, http://dx.doi.org/10.1189/
jlb.1109766.
23. Amantea D, Nappi G, Bernardi G, et al. Post-ischemic
brain damage: pathophysiology and role of inﬂamma-
tory mediators. FEBS J. 2009;276:13--26, http://dx.doi.org/
10.1111/j.1742-4658.2008.06766.x.
24. Minami M, Katayama T, Satoh M. Brain cytokines and
chemokines: roles in ischemic injury and pain. J Pharma-
col Sci. 2006;100:461--70, http://dx.doi.org/10.1254/jphs.
CRJ06005X.
25. Ohab JJ, Fleming S, Blesch A, et al. A neurovascular niche
for neurogenesis after stroke. J Neurosci. 2006;26:13007--16,
http://dx.doi.org/10.1523/JNEUROSCI.4323-06.2006.
26. Bajetto A, Bonavia R, Barbero S, et al. Chemokines
and their receptors in the central nervous system. J
Neurochem. 2001;22:1311--29, http://dx.doi.org/10.1006/
frne.2001.0214.
27. Wang Y, Deng Y, Zhou GQ. SDF-1a/CXCR4-mediated migration
of systemically transplanted bone marrow stromal cells
towards ischemic brain lesion in a rat model. Brain Res.
2008;1195:104--12, http://dx.doi.org/10.1016/j.brainres.
2007.11.068.
28. Zhang ZG, Chopp M. Neurorestorative therapies for stroke:
underlying mechanisms and translation to the clinic.
Lancet Neurol. 2009;8:491--500, http://dx.doi.org/10.1016/
S1474-4422(09)70061-4.
29. Zhang R, Wang Y, Zhang L, et al. Sildenaﬁl (Viagra)
induces neurogenesis and promotes functional recov-
ery after stroke in rats. Stroke. 2002;33:2675--80,
http://dx.doi.org/10.1161/01.STR.0000034399.95249.59.
30. Cramer SC. Repairing the human brain after stroke. II. Restor-
ative therapies. Ann Neurol. 2008;63:549--60, http://dx.
doi.org/10.1002/ana.21412.
31. Langhorne P, Bernhardt J, Kwakkel G, et al. Stroke rehabilita-
tion. Lancet. 2011;377:1693--702, http://dx.doi.org/10.1016/
S0140-6736(11)60325-5.
32. Wolf SL, Winstein CJ, Miller JP, et al. Effect of constraint-
induced movement therapy on upper extremity function 3
to 9 months after stroke: the EXCITE randomized clinical
trial. JAMA. 2015;296:2095--104, http://dx.doi.org/10.1001/
jama.296.17.2095.
33. Becker AJ, McCulloch EA, Till JE. Cytological demonstra-
tion of the clonal mature of spleen colonies derived from
transplanted mouse marrow cells. Nature. 1963;197:452--4,
http://dx.doi.org/10.1038/197452a0.
34. Trounson A, Thakar RG, Lomax G, et al. Clinical trials for
stem cell therapies. BMC Med. 2011;9:52, http://dx.doi.org/
10.1186/1741-7015-9-52.
35. Rippon H, Bishop A. Embryonic stem cells. Cell Prolif.
2004;37:23--34.
36. Thomson JA, Itskovitz-eldor J, Shapiro SS, et al. Embryonic
stem cell lines derived from human blastocysts. Science.
1998;282:1145--8.
37. Young HE, Black ASAC. Adult stem cells. Anat Rec Part A.
2004;276A:75--102, http://dx.doi.org/10.1002/ar.a.10134.
38. Takahashi K, Yamanaka S. Induction of pluripotent stem cells
from mouse embryonic and adult ﬁbroblast cultures by deﬁned
factors. Cell. 2006;126:663--76.
39. Eriksson PS, Perﬁlieva E, Björk-Eriksson T, et al. Neurogenesis
in the adult human hippocampus. Nat Med. 1998;4:1313--7,Please  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
http://dx.doi.org/10.1038/3305.
40. Gage FH. Mammalian neural stem cells. Science.
2000;287:1433--8, http://dx.doi.org/10.1126/science.287.
5457.1433. PRESS
9
41. Zhang RL, Zhang ZG, Zhang L, et al. Proliferation
and differentiation of progenitor cells in the cortex
and the subventricular zone in the adult rat after
focal cerebral ischemia. Neuroscience. 2001;105:33--41,
http://dx.doi.org/10.1016/S0306-4522(01)00117-8.
42. Liu J, Solway K, Messing RO, et al. Increased neurogenesis in
the dentate gyrus after transient global ischemia in gerbils. J
Neurosci. 1998;18:7768--78.
43. Parent JM, Vexler ZS, Gong C, et al. Rat forebrain neurogenesis
and striatal neuron replacement after focal stroke. Ann Neu-
rol. 2002;52:802--13, http://dx.doi.org/10.1002/ana.10393.
44. Curtis MA, Penney EB, Pearson AG, et al. Increased cell pro-
liferation and neurogenesis in the adult human Huntington’s
disease brain. Proc Natl Acad Sci U S A. 2003;100:9023--7,
http://dx.doi.org/10.1073/pnas.1532244100.
45. Jin K, Peel AL, Mao XO, et al. Increased hippocam-
pal neurogenesis in Alzheimer’s disease. Proc Natl Acad
Sci U S A. 2004;101:343--7, http://dx.doi.org/10.1073/
pnas.2634794100.
46. Arvidsson A, Collin T, Kirik D, et al. Neuronal replacement
from endogenous precursors in the adult brain after stroke.
Nat Med. 2002;8:963--70, http://dx.doi.org/10.1038/nm747.
47. Iskander A, Knight RA, Zhang ZG, et al. Intravenous admin-
istration of human umbilical cord blood-derived AC133+
endothelial progenitor cells in rat stroke model reduces
infarct volume: magnetic resonance imaging and histo-
logical ﬁndings. Stem Cells Transl Med. 2013;70:3--714,
http://dx.doi.org/10.5966/sctm. 2013-0066.
48. Hou SW, Wang YQ, Xu M, et al. Functional integration
of newly generated neurons into striatum after cerebral
ischemia in the adult rat brain. Stroke. 2008;39:2837--44,
http://dx.doi.org/10.1161/STROKEAHA.107.510982.
49. Zhang RL, Zhang ZG, Roberts C, et al. Lengthening
the G(1) phase of neural progenitor cells is concurrent
with an increase of symmetric neuron generating division
after stroke. J Cereb Blood Flow Metab. 2008;28:602--11,
http://dx.doi.org/10.1038/sj.jcbfm.9600556.
50. Vojtek AB, Taylor J, DeRuiter SL, et al. Akt regulates
basic helix-loop-helix transcription factor-coactivator com-
plex formation and activity during neuronal differentiation.
Mol Cell Biol. 2003;23:4417--27, http://dx.doi.org/10.1128/
MCB.23.13.4417.
51. Katakowski M, Zhang ZG, Chen J, et al. Phosphoinosi-
tide 3-kinase promotes adult subventricular neuroblast
migration after stroke. J Neurosci Res. 2003;74:494--501,
http://dx.doi.org/10.1002/jnr.10775.
52. Liu XS, Zhang ZG, Zhang RL, et al. Stroke induces gene
proﬁle changes associated with neurogenesis and angio-
genesis in adult subventricular zone progenitor cells. J
Cereb Blood Flow Metab. 2007;27:564--74, http://dx.doi.org/
10.1038/sj.jcbfm.9600371.
53. Birbrair A, Frenette PS. Niche heterogeneity in the bone mar-
row. Ann NY Acad Sci. 2016;1370:82--96, http://dx.doi.org/
10.1111/nyas.13016.
54. Cogle CR, Yachnis AT, Laywell ED, et al. Bone marrow
transdifferentiation in brain after transplantation: a retro-
spective study. Lancet. 2004;363:1432--7, http://dx.doi.org/
10.1016/S0140-6736(04)16102-3.
55. Dominici M, Blanc K, Le Mueller I, et al. Minimal crite-
ria for deﬁning multipotent mesenchymal stromal cells.
Int Soc Cell Therapy Position Statement. 2006;8:315--7,
http://dx.doi.org/10.1080/14653240600855905.
56. Li Y, Chen J, Chen XG, et al. Human marrow stro-
mal  cell therapy for stroke in rat: neurotrophins Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
and functional recovery. Neurology. 2002;59:514--23,
http://dx.doi.org/10.1212/WNL.59.4.514.
57. Caplan A. Why  are MSCs therapeutic? New data: new insight.
J Pathol. 2009;217:318--24, http://dx.doi.org/10.1002/path.
 IN+ModelR
1ARTICLEMU-85; No. of Pages 12
0  
58. Sigurjonsson OE, Perreault M-C, Egeland T, et al. Adult
human hematopoietic stem cells produce neurons efﬁ-
ciently in the regenerating chicken embryo spinal
cord. Proc Natl Acad Sci U S A. 2005;102:5227--32,
http://dx.doi.org/10.1073/pnas.0501029102.
59. Doyonnas R, LaBarge MA, Sacco A, et al. Hematopoietic contri-
bution to skeletal muscle regeneration by myelomonocytic
precursors. Proc Natl Acad Sci U S A. 2004;101:13507--12,
http://dx.doi.org/10.1073/pnas.0405361101.
60. Orlic D, Kajstura J, Chimenti S, et al. Mobilized bone mar-
row cells repair the infarcted heart, improving function
and survival. Proc Natl Acad Sci U S A. 2001;98:10344--9,
http://dx.doi.org/10.1073/pnas.181177898.
61. Martino G, Marco B, Peruzzotti-Jametti L. Therapeutic
stem cell plasticity orchestrates tissue plasticity. Brain.
2011;134:1585--7, http://dx.doi.org/10.1093/brain/awr115.
62. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, et al.
Safety and immunological effects of mesenchymal stem
cell transplantation in patients with multiple sclerosis and
amyotrophic lateral sclerosis. Arch Neurol. 2010;67:1187--94,
http://dx.doi.org/10.1001/archneurol.2010.248.
63. Jendelova P, Fales I, Andersson B, et al. Magnetic resonance
tracking of human CD34+ progenitor cells separated by means
of immunomagnetic selection and transplanted into injured rat
brain. Cell Transplant. 2005;14:173--82.
64. Lin S-Z, Shyu W-C, Liu S-P, et al. Intracerebral implanta-
tion of autologous peripheral blood stem cells (CD34) in old
ischemic stroke patients. Cell Transplant. 2014;23:1599--612,
http://dx.doi.org/10.3727/096368914X678562.
65. Pencea V, Bingaman KD, Wiegand SJ, et al. Infusion of brain-
derived neurotrophic factor into the lateral ventricle of the
adult rat leads to new neurons in the parenchyma of the
striatum, septum, thalamus, and hypothalamus. J Neurosci.
2001;21:6706--17.
66. Shen LH, Li Y, Chen J, et al. Therapeutic beneﬁt of bone mar-
row stromal cells administered 1 month after stroke. J Cereb
Blood Flow Metab. 2007;27:6--13.
67. Moniche F, Gonzalez A, Gonzalez-Marcos JR, et al. Intra-
arterial bone marrow mononuclear cells in ischemic
stroke: a pilot clinical trial. Stroke. 2012;43:2242--4,
http://dx.doi.org/10.1161/strokeaha.112.659409.
68. Chen J, Li Y, Katakowski M, et al. Intravenous bone marrow
stromal cell therapy reduces apoptosis and promotes endoge-
nous cell proliferation after stroke in female rat. J Neurosci
Res. 2003;73:778--86, http://dx.doi.org/10.1002/jnr.10691.
69. Li Y, Chen J, Zhang CL, et al. Gliosis and brain remodeling
after treatment of stroke in rats with marrow stromal cells.
Glia. 2005;49:407--17, http://dx.doi.org/10.1002/glia.20126.
70. Shen LH, Li Y, Gao Q, et al. Down-regulation of neu-
rocan expression in reactive astrocytes promotes axonal
regeneration and facilitates the neurorestorative effects of
bone marrow stromal cells in the ischemic rat brain. Glia.
2008;56:1747--54, http://dx.doi.org/10.1002/glia.20722.
71. Pavlichenko N, Sokolova I, Vijde S, et al. Mesenchy-
mal stem cells transplantation could be beneﬁcial
for treatment of experimental ischemic stroke in rats.
Brain Res. 2008;1233:203--13, http://dx.doi.org/10.1016/
j.brainres.2008.06.123.
72. Carter BD, Dobrowsky RT, Chao MV, et al. Marrow stromal
cells as stem cells for nonhematopoietic tissues. Science.
1997;276(April):71--4.
73. Terada N, Hamazaki T, Oka M, et al. Bone mar-
row cells adopt the phenotype of other cells by
spontaneous cell fusion. Nature. 2002;416:542--5,Please  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
http://dx.doi.org/10.1038/nature730.
74. Bang OY, Lee JS, Lee PH, et al. Autologous mesenchymal
stem cell transplantation in stroke patients. Ann Neurol.
2005;57:874--82, http://dx.doi.org/10.1002/ana.20501. PRESS
D.M.  Martínez-Garza  et  al.
75. Le Blanc K, Tammik C, Rosendahl K, et al. HLA expression
and immunologic properties of differentiated and undiffer-
entiated mesenchymal stem cells. Exp Hematol. 2003;31:
890--6.
76. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell ther-
apy with mesenchymal stromal cells (SafeCell): a systematic
review and meta-analysis of clinical trials. PLoS ONE. 2012;7,
http://dx.doi.org/10.1371/journal.pone.0047559.
77. Krupinski J, Kaluza J, Kumar P, et al. Role of angiogen-
esis in patients with cerebral ischemic stroke. Stroke.
1994;25:1794--8, http://dx.doi.org/10.1161/01.STR.25.9.
1794.
78. Krupinski J, Kaluza JPK, Wan M, et al. Prognostic value of blood
vessel density in ischaemic stroke. Lancet. 1993;342:742.
79. Wang L, Zhang Z, Wang Y, et al. Treatment of stroke
with erythropoietin enhances neurogenesis and angio-
genesis and improves neurological function in rats.
Stroke. 2004;35:1732--7, http://dx.doi.org/10.1161/
01.STR.0000132196.49028.a4.
80. Zhang ZG, Zhang L, Tsang W,  et al. Correlation of VEGF
and angiopoietin expression with disruption of blood-
brain barrier and angiogenesis after focal cerebral
ischemia. J Cereb Blood Flow Metab. 2002;22:379--92,
http://dx.doi.org/10.1097/00004647-200204000-00002.
81. Teng H, Zhang ZG, Wang L, et al. Coupling of angio-
genesis and neurogenesis in cultured endothelial cells
and neural progenitor cells after stroke. J Cereb Blood
Flow Metab. 2008;28:764--71, http://dx.doi.org/10.1038/
sj.jcbfm.9600573.
82. Wang L, Chopp M, Gregg SR, et al. Neural progenitor cells
treated with EPO induce angiogenesis through the produc-
tion of VEGF. J Cereb Blood Flow Metab. 2008;28:1361--8,
http://dx.doi.org/10.1038/jcbfm.2008.32.
83. Chen J, Zhang ZG, Li Y, et al. Intravenous administra-
tion of human bone marrow boundary zone after stroke in
rats. Circ Res. 2003;92:692--9, http://dx.doi.org/10.1161/
01.RES.0000063425.51108.8D.
84. Chen J, Li Y, Zhang R, et al. Combination therapy of
stroke in rats with a nitric oxide donor and human bone
marrow stromal cells enhances angiogenesis and neurogen-
esis. Brain Res. 2004;1005:21--8, http://dx.doi.org/10.1016/
j.brainres.2003.11.080.
85. Bhasin A, Srivastava MVP, Mohanty S, et al. Stem cell
therapy: a clinical trial of stroke. Clin Neurol Neurosurg.
2013;115:1003--8, http://dx.doi.org/10.1016/j.clineuro.
2012.10.015.
86. Knoepﬂer PS. Deconstructing stem cell tumorigenicity:
a roadmap to safe regenerative medicine. Stem Cells.
2009;27:1050--6, http://dx.doi.org/10.1002/stem.37.
87. Baldwin T. Mortality and human embryo research. EMBO Rep.
2009;10:299--300, http://dx.doi.org/10.1038/embor.2009.37.
88. Okano H, Nakamura M, Yoshida K, et al. Steps toward safe
cell therapy using induced pluripotent stem cells. Circ Res.
2013;112:523--33, http://dx.doi.org/10.1161/CIRCRESAHA.
111.256149.
89. Fujita K. The dark side of induced pluripotency. Nature.
2011;471:46--7, http://dx.doi.org/10.1029/1999GL006075.
90. Gutierrez-Aranda I, Ramos-Mejía V, Bueno C, et al. Human
induced pluripotent stem cells develop teratoma more
efﬁciently and faster than human embryonic stem cells regard-
less the site of injection. Stem Cells. 2010;28:1568--70,
http://dx.doi.org/10.1002/stem.471.
91. Kondziolka D, Wechsler L, Goldstein S, et al. Transplantation
of cultured human neuronal cells for patients with stroke. Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
Neurology. 2000;55:565--9, http://dx.doi.org/10.1212/
WNL.55.4.565.
92. Prabhakaran S, Zarahn E, Riley C, et al. Inter-individual
variability in the capacity for motor recovery after ischemic
 IN+Model
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1ARTICLERMU-85; No. of Pages 12
Stem  cell  therapy  for  stroke  
stroke. Neurorehabil Neural Repair. 2007;22(1):64--71,
http://dx.doi.org/10.1177/1545968307305302.
93. Cramer SC, Chopp M. Recovery recapitulates ontogeny.
Trends Neurosci. 2000;23:265--71, http://dx.doi.org/10.1016/
S0166-2236(00)01562-9.
94. Savitz SI, Chopp M, Deans R, et al. Stem cell therapy
as an emerging paradigm for stroke (STEPS) II. Stroke.
2011;42:825--9, http://dx.doi.org/10.1161/STROKEAHA.110.
601914.
95. Savitz SI, Cramer SC, Wechsler L, et al. Stem cells
as an emerging paradigm in stroke 3: enhancing the
development of clinical trials. Stroke. 2014;45:634--9,
http://dx.doi.org/10.1161/STROKEAHA.113.003379.
96. Lindenberg R, Renga V, Zhu LL, et al. Structural integrity
of corticospinal motor ﬁbers predicts motor impair-
ment in chronic stroke. Neurology. 2010;74:280--7,
http://dx.doi.org/10.1212/WNL.0b013e3181ccc6d9.
97. Lee SY, Lim JY, Kang EK, et al. Prediction of good func-
tional recovery after stroke based on combined motor and
somatosensory evoked potential ﬁndings. J Rehabil Med.
2010;42:16--20, http://dx.doi.org/10.2340/16501977-0475.
98. Chen J, Li Y, Wang L, et al. Therapeutic beneﬁt of intra-
cerebral transplantation of bone marrow stromal cells after
cerebral ischemia in rats. J Neurol Sci. 2001;189:49--57,
http://dx.doi.org/10.1016/S0022-510X(01)00557-3.
99. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic
graft-versus-host disease after HLA-identical sibling bone mar-
row transplantation. Blood. 1990;75:2459--64.
100. Sprigg N, Bath PM, Zhao L, et al. Granulocyte-colony-
stimulating factor mobilizes bone marrow stem cells in
patients with subacute ischemic stroke: the stem cell trial of
recovery enhancement after stroke (STEMS) pilot randomized,
controlled trial (ISRCTN 16784092). Stroke. 2006;37:2979--83,
http://dx.doi.org/10.1161/01.STR.0000248763.49831.c3.
101. Alasheev AM, Belkin AA, Leiderman IN, et al. Granulocyte-
colony-stimulating Factor for Acute Ischemic Stroke:
A Randomized Controlled Trial (STEMTHER). Transl
Stroke Res. 2011;2:358--65, http://dx.doi.org/10.1007/
s12975-011-0091-3.
102. England TJ, Abaei M, Auer DP, et al. Granulocyte-colony stimu-
lating factor for mobilizing bone marrow stem cells in subacute
stroke: the stem cell trial of recovery enhancement after
stroke 2 randomized controlled trial. Stroke. 2012;43:405--11,
http://dx.doi.org/10.1161/STROKEAHA.111.636449.
103. Jcrgensen HS, Nakayama H, Raaschou HO, et al. Outcome and
time course of recovery in stroke. Part II: time course of recov-
ery. The Copenhagen Stroke Study. Arch Phys Med Rehabil.
1995;76:406--12.
104. Kondziolka D, Steinberg GK, Wechsler L, et al. Neuro-
transplantation for patients with subcortical motor stroke:
a phase 2 randomized trial. J Neurosurg. 2005;103:38--45,
http://dx.doi.org/10.3171/jns.2005.103.1.0038.
105. Komatsu K, Honmou O, Suzuki J, et al. Therapeutic time
window of mesenchymal stem cells derived from bone mar-
row after cerebral ischemia. Brain Res. 2010;1334:84--92,
http://dx.doi.org/10.1016/j.brainres.2010.04.006.
106. Sharma A, Sane H, Gokulchandran N, et al. Autologous
bone marrow mononuclear cells intrathecal transplanta-
tion in chronic stroke. Stroke Res Treat. 2014;2014:1--9,
http://dx.doi.org/10.1155/2014/234095.
107. Savitz SI, Misra V, Kasam M, et al. Intravenous autologous bone
marrow mononuclear cells for ischemic stroke. Ann Neurol.
2011;70:59--69, http://dx.doi.org/10.1002/ana.22458.
108. Smith HK, Gavins FN. The potential of stem cell therapyPlease  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
for stroke: is PISCES the sign? FASEB J. 2012;26:2239--52,
http://dx.doi.org/10.1096/fj.11-195719.
109. Rodríguez-Frutos B, Otero-Ortega L, Gutiérrez-Fernández M,
et al. Stem cell therapy and administration routes after stroke.
1 PRESS
11
Transl Stroke Res. 2016:1--10, http://dx.doi.org/10.1007/
s12975-016-0482-6.
10. Lee JS, Hong JM, Moon GJ, et al. A long-term follow-
up study of intravenous autologous mesenchymal stem cell
transplantation in patients with ischemic stroke. Stem Cells.
2010;28:1099--106, http://dx.doi.org/10.1002/stem.430.
11. Prasad K, Sharma A, Garg A, et al. Intravenous autologous bone
marrow mononuclear stem cell therapy for ischemic stroke:
a multicentric, randomized trial. Stroke. 2014;45:3618--24,
http://dx.doi.org/10.1161/STROKEAHA.114.007028.
12. Kaur C, Ling EA. Blood brain barrier in hypoxic-
ischemic conditions. Curr Neurovasc Res. 2008;5:71--81,
http://dx.doi.org/10.2174/156720208783565645.
13. Greenwood J. Mechanisms of blood--brain barrier breakdown.
Neuroradiology. 1991;33:95--100.
14. Liu L, Eckert MA, Riazifar H, et al. From blood to the
brain: can systemically transplanted mesenchymal stem cells
cross the blood--brain barrier? Stem Cells Int. 2013;2013:1--7,
http://dx.doi.org/10.1155/2013/435093.
15. Vulliet PR, Greeley M, Halloran SM, et al. Intra-
coronary arterial injection of mesenchymal stromal cells
and microinfarction in dogs. Lancet. 2004;363:783--4,
http://dx.doi.org/10.1016/S0140-6736(04)15695-X.
16. Friedrich MAG, Martins MP, Araújo MD, et al. Intra-arterial
infusion of autologous bone marrow mononuclear cells in
patients with moderate to severe middle cerebral artery
acute ischemic stroke. Cell Transplant. 2012;21 Suppl 1:13--22,
http://dx.doi.org/10.3727/096368912X612512.
17. Battistella V, Freitas GR De, Dias V, et al. Safety of autologous
bone marrow mononuclear cell transplantation in patients
with nonacute ischemic stroke. Futur Med. 2011;6:45--52.
18. Lu D, Mahmood A, Wang L, et al. Adult bone marrow stromal
cells administered intravenously to rats after traumatic brain
injury migrate into brain and improve neurological outcome.
Neuroreport. 2001;12:559--63.
19. Lim JY, Jeong CH, Jun JA, et al. Therapeutic effects of
human umbilical cord blood-derived mesenchymal stem cells
after intrathecal administration by lumbar puncture in a rat
model of cerebral ischemia. Stem Cell Res Ther. 2011;2:38,
http://dx.doi.org/10.1186/scrt79.
20. Mancías-Guerra C, Marroquín-Escamilla AR, González-
Llano O, et al. Safety and tolerability of intrathecal
delivery of autologous bone marrow nucleated cells in
children with cerebral palsy: an open-label phase I trial.
Cytotherapy. 2014;16:810--20, http://dx.doi.org/10.1016/
j.jcyt.2014.01.008.
21. Yang W-Z, Zhang Y, Wu F, et al. Safety evaluation of
allogeneic umbilical cord blood mononuclear cell ther-
apy for degenerative conditions. J Transl Med. 2010;8:75,
http://dx.doi.org/10.1186/1479-5876-8-75.
22. Mehta T, Feroz A, Thakkar U, et al. Subarachnoid
placement of stem cells in neurological disorders. Trans-
plant Proc. 2008;40:1145--7, http://dx.doi.org/10.1016/
j.transproceed.2008.03.026.
23. Hurst RW, Peter Bosch E, Morris JM, et al. Inﬂam-
matory hypertrophic cauda equina following intrathecal
neural stem cell injection. Muscle Nerve. 2013;48:831--5,
http://dx.doi.org/10.1002/mus.23920.
24. Alderazi YJ, Coons SW, Chapman K. Catastrophic
demyelinating encephalomyelitis after intrathecal and
intravenous stem cell transplantation in a patient
with multiple sclerosis. J Child Neurol. 2012;27:632--5,
http://dx.doi.org/10.1177/0883073811422831.
25. Kawarai T. Spinal myoclonus resulting from intrathecal Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
administration of human neural stem cells. Mov Disord.
2011;26:1353--4, http://dx.doi.org/10.1002/mds.22959.
26. Qiao L-Y, Huang F-J, Zhao M, et al. A two-year follow-up
study of cotransplantation with neural stem/progenitor
 IN+ModelR
1
1
1
1
1
1
1
response to subventricular zone cell transplantation mea-
sured by iterative self-organizing data analysis techniqueARTICLEMU-85; No. of Pages 12
2  
cells and mesenchymal stromal cells in ischemic stroke
patients. Cell Transplant. 2014;23 Suppl 1:65--72,
http://dx.doi.org/10.3727/096368914X684961.
27. Stilley CS, Ryan CM, Kondziolka D, et al. Changes in
cognitive function after neuronal cell transplantation
for basal ganglia stroke. Neurology. 2004;132:0--1322,
http://dx.doi.org/10.1212/01.WNL.0000140700.44904.53.
28. Saenger AK, Christenson RH. Stroke Biomarkers: progress
and challenges for diagnosis, prognosis, differentiation, and
treatment. Clin Chem. 2010;56:21--33, http://dx.doi.org/
10.1373/clinchem.2009.133801.Please  cite  this  article  in  press  as:  Martínez-Garza  DM,  et  al.
stroke.  Medicina  Universitaria.  2016.  http://dx.doi.org/10.101
29. Cramer SC, Koroshetz WJ, Finklestein SP. The case for
modality speciﬁc outcome measures in clinical trials of
stroke recovery promoting agents. Stroke. 2007;38:1393--5,
http://dx.doi.org/10.1161/01.STR.0000260087.67462.80. PRESS
D.M.  Martínez-Garza  et  al.
30. Ding G, Jiang Q, Li L, et al. Magnetic resonance imaging inves-
tigation of axonal remodeling and angiogensis after embolic
stroke in sildenaﬁl treated rats. J Cereb Blood Flow Metab.
2008;28:1440--8, http://dx.doi.org/10.1038/jcbfm.2008.33.
31. Jiang Q, Zheng GZ, Guang LD, et al. Investigation of
neural progenitor cell induced angiogenesis after embolic
stroke in rat using MRI. Neuroimage. 2005;28:698--707,
http://dx.doi.org/10.1016/j.neuroimage.2005.06.063.
32. Li L, Jiang Q, Zhang L, et al. Ischemic cerebral tissue Current  state  and  perspectives  of  stem  cell  therapy  for
6/j.rmu.2016.07.005
algorithm. J Cereb Blood Flow Metab. 2006;26:1366--77,
http://dx.doi.org/10.1038/sj.jcbfm.9600288.
